# Neoadjuvant Therapy for Locally Advanced Rectal Cancer

> **NCT06853769** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 48 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Anlotinib hydrochloride,Penpulimab

## Key facts

- **NCT ID:** NCT06853769
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06853769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06853769, "Neoadjuvant Therapy for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06853769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*